The third quarter in the life sciences space saw notable developments in significant agency enforcement actions: The FTC abandoned its pursuit of a novel theory and settled its Amgen/Horizon lawsuit.
The FTC’s Amgen/Horizon Lawsuit Ends With a Whimper - We covered the FTC’s investigation into (and litigation challenging) Amgen’s $28.3 billion acquisition of rare.
More than two dozen life science, pharmaceutical and biotech organizations partner to form the Partnership for the U.S. Life Science Ecosystem (PULSE).